{
    "clinical_study": {
        "@rank": "63840", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "Continuous dosing of ABT-199 QD (once daily) beginning with dose-escalation on Week 1 Day 1"
        }, 
        "brief_summary": {
            "textblock": "A Phase 2, Open-Label, Multicenter study evaluating the preliminary efficacy and safety of\n      ABT-199 administered orally in patients with AML."
        }, 
        "brief_title": "A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "AML", 
            "Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histological or cytological confirmation of relapsed or refractory AML (by World\n             Health Organization (WHO) classification) or untreated AML in patients who are unfit\n             for intensive therapy.\n\n          2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.\n\n          3. Subject must have adequate renal function as demonstrated by a calculated creatinine\n             clearance \u2265 50 mL/min; determined via urine collection for 24-hour creatinine\n             clearance or by the Cockcroft Gault formula using ideal body mass (IBM) instead of\n             mass.\n\n          4. Subject must have adequate liver function.\n\n        Exclusion Criteria:\n\n          1. Subject has received acute anti-cancer therapy including chemotherapy, immunotherapy,\n             radiotherapy, hormonal or any investigational therapy within 14 days or 5 half-lives\n             (whichever is shorter) prior to first dose of ABT-199.\n\n          2. Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks\n             prior to the first dose of study drug.\n\n          3. Subject has received Potent CYP3A inducers (such as rifampin, carbamazepine,\n             phenytoin and St. John's wort and Warfarin or requires the use of warfarin (due to\n             potential drug-drug interactions that may potentially increase the exposure of\n             warfarin and complications of this effect) within 7 days prior to the first dose of\n             study drug.\n\n          4. Subject has received CYP3A inhibitors (such as fluconazole, ketoconazole, and\n             clarithromycin) within 5 days prior to the first dose of study drug.\n\n          5. Subject has a white blood cell count > 25 x 10^9/L.\n\n          6. Subject has acute promyelocytic leukemia (French-American-British Class M3 AML).\n\n          7. Subjects with known active CNS disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994837", 
            "org_study_id": "M14-212"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "description": "Tablet", 
            "intervention_name": "ABT-199", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GDC-0199", 
            "Myeloid Leukemia", 
            "ABT-199", 
            "Acute Myeloid Leukemia", 
            "AML", 
            "Acute Myelogenous Leukemia"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Site Reference ID/Investigator# 117476"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117476", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Site Reference ID/Investigator# 117158"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117158", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Site Reference ID/Investigator# 117795"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117795", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "Site Reference ID/Investigator# 117475"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 117475", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)", 
        "overall_contact": {
            "email": "nancy.falotico@abbvie.com", 
            "last_name": "Nancy  Falotico", 
            "phone": "847-937-0370"
        }, 
        "overall_contact_backup": {
            "email": "michael.dawson@abbvie.com", 
            "last_name": "Michael  Dawson, BS", 
            "phone": "847-938-9467"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Jalaja  Potluri, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the preliminary efficacy of ABT-199 administered orally in patients with relapsed/refractory AML or frontline in patients with AML who are unfit for intensive therapy.", 
            "measure": "Efficacy will be measured by overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Complete response rate will be defined as the proportion of subject who achieved a complete response per the International Working Group (IWG) criteria for AML.", 
                "measure": "Complete response (CR) rate", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Duration of response will be defined as the number of days from the date of first response per the IWG criteria for AML to the earliest recurrence or Progressive Disease (PD).", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Time to progression will be defined as the number of days from the date of enrollment to the date of earliest progression.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Progression-free survival will be defined as the number of days from the date of enrollment to the date of earliest progression or death.  If the subject does not experience disease progression or death, then the data will be censored at the date of the last disease assessment.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Overall survival will be defined as the number of days from the date of enrollment to the date of death for all dosed subjects", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The percent of subjects who move on to stem cell transplant will be summarized.", 
                "measure": "Percent of subjects who move on to stem cell transplant", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The rate of Minimal Residual Disease (MRD) negativity will be defined as the number of subjects who had MRD negativity status.", 
                "measure": "Rate of Minimal Residual Disease (MRD) negativity in subjects", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study.", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Body temperature, weight, blood pressure, heart rate.", 
                "measure": "Change in physical exam findings, including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day -1 up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Chemistry, hematology, urinalysis", 
                "measure": "Change in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day -1 up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study.", 
                "measure": "Percentage of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Complete response with incomplete marrow recovery (CRi) will be defined as the proportion of subjects who achieve a CRi based on the IWG criteria for AML.", 
                "measure": "Complete response with incomplete marrow recovery (CRi)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "Partial response will be defined as the proportion of subjects who achieved a PR per the IWG criteria for AML.", 
                "measure": "Partial response (PR)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}